SPK Acquisition Corp.
Definitive Agreement
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $50M
- Underwriters
- Focus
- Telecommunications, Media, Technology, TMT
- SEC Filings
- 1848097
- Public Embarc Page
- https://embarc.com/capital/spac/1848097/SPK/spk-acquisition
SPAC Leadership
Information on the SPAC leadership.
- Chairman and Chief Executive OfficerSophie Ye Tao
- Chief Financial Officer and DirectorPhilip Chun-Hun Kwan
- DirectorJustin Chang
- DirectorBryant Chou
- DirectorGreg Chang
Target Information
Information on the SPAC target for merger.
- Company
- Varian Biopharmaceuticals, Inc.
- Presentation
- Investor Presentation (SEC) on 2022-03-01
- Description
- Varian Bio is "a private, precision oncology company developing novel therapeutics for the treatment of cancer."